Burjeel Holdings Plc · ADX:BURJEEL
Burjeel — Q3 2024 Earnings Presentation
22 slides from Burjeel's earnings presentation, November 2024
Slide 1: Q3 & 9M 2024 Leading Super-Specialty Healthcare Provider in MENA
November 2024 Q3 & 9M 2024 Leading Super-Specialty Healthcare Provider in MENA
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burjeel Holdings PLC None of the Company or its subsidiaries or any of their affiliates or based on publicly available information and non-public advisors make any representation or warranty as to the fairness, information to assist you in making a p
Slide 3: Key Highlights
Key Highlights Leading Super-Specialty Healthcare Provider in MENA
Slide 4: Key Highlights
Key Highlights Financial Highlights Recent Business Developments Q3’24 9M’24 Expanding UAE Primary Care Network Revenue AED 1,319m AED 3,705m In line with the UAE’s vision, nine community-based primary care clinics will be launched within the next few months across Abu Dhabi, Al Ain, and Dubai. Thes
Slide 5: Super-Specialty Care Offering Driving Patient Yields
Super-Specialty Care Offering Driving Patient Yields Q3’24 Medical milestones across key complex specialties Super-specialty care performance… …drives patient yield Liver & Kidney transplants Multi-organ transplants 26 (100% success rate) Since 2024 AED 250,000 – 1,000,000 Fetal surgeries Fetal surg
Slide 6: Advancing Women & Children's Healthcare Offering
Advancing Women & Children’s Healthcare Offering Partnering with the "Father of Fetal The UAE's largest fertility center Medicine," to provide fetal care for high- offers comprehensive treatments, risk pregnancies. First in MENA to including egg retrieval, AI embryo perform in-utero spina bifida rep
Slide 7: Leading Cancer Care Network in the UAE
Leading Cancer Care Network in the UAE Burjeel Cancer Burjeel’s Clinical Comprehensive Institute (Burjeel Oncology Governance Oncology Medical City) Network & Research Services Cancer MDT & Clinical Guidelines Pathology, AI & Molecular Diagnostics Abu Dhabi Medical Oncology (HIPEC) Personalized Pati
Slide 8: Accelerating Expansion Across Saudi Arabia Through Disruptive Healthcare Innovations
Accelerating Expansion Across Saudi Arabia Through Disruptive Healthcare Innovations PhysioTherabia – 28 Burjeel One – First Day Surgery Center in Riyadh centers launched Performance Upadate across 9 cities Tabouk • Located in Irqah, Northwestern Riyadh, with an estimated +100% AED 1.5m vs 3.3m Al J
Slide 9: Performance Review
Performance Review Leading Super-Specialty Healthcare Provider in MENA
Slide 10: Delivering Strong Patient Footfall Growth On the Back of Continued Market Penetration
Delivering Strong Patient Footfall Growth On the Back of Continued Market Penetration Group inpatient footfall, k Group outpatient footfall, k % bed occupancy % OP utilisation 63% 70% 60% 66% 69% 68% 71% 69% • The Group achieved strong inpatient footfall • Outpatient footfall growth in Q3’24 growth
Slide 11: Ramping Up Revenue Along with Investments in Future Patient Growth
Ramping Up Revenue Along with Investments in Future Patient Growth Group Revenue, AED m Group EBITDA, AED m YoY EBITDA margin YoY 1,319 • Top-line growth accelerated in Q3’24, with a (reported) • Group EBITDA grew YoY in Q3’24 despite +14.1% 12% rise in patient footfall despite a high +5.1% AED 16 m
Slide 12: Burjeel Medical City Strategically Positioned to Drive High-Yield Patient Growth & Margin Expansion
Burjeel Medical City Strategically Positioned to Drive High-Yield Patient Growth & Margin Expansion Total patients, k Revenue, AED m1 EBITDA, AED m1 % bed occupancy % EBITDA margin 50% 65% 46% 60% 16.1% 16.0% 14.7% 16.1% +19.3% +28.1% 879 +31.2% 388 737 142 303 +16.5% 108 +30.9% +15.7% 306 142 262 4
Slide 13: Ongoing Investments in Super-Specialty & Network Expansion to Unlock Significant Growth Potential
Ongoing Investments in Super-Specialty & Network Expansion to Unlock Significant Growth Potential Group OPEX breakdown,1 as % of revenue Group EBITDA analysis, AED m % EBITDA margin 77.8% 79.6% 78.6% 80.1% 22.5% 20.7% 8.4% 9.3% 8.9% 9.2% +163 (46) 1.8% 2.2% 1.7% 2.0% YoY (71) Other3 +5.1% 25.1% 25.5
Slide 14: Free Cash Flow & Net Profit Performance
Free Cash Flow & Net Profit Performance Free cash flow,1 AED m Net profit analysis, AED m % FCF conversion2 % Net profit margin 64% 42% 51% 45% 49% 11.9% 11.4% 10.4% 523 497 +163 (151) YoY YoY 366 364 +9.8% +0.2% 331 137 +1 +0.3 151 (13) 137 2021 2022 2023 9M’23 9M’24 Q3’23 Q3'23 Revenue Revenue OPE
Slide 15: Maintaining a Robust Balance Sheet
Maintaining a Robust Balance Sheet AED m FY 2022 FY 2023 9M 2024 Debt maturity as of 30 September 2024 Bank balances and cash 150 170 138 Interest-bearing loans and borrowings 1,261 1,164 1,148 219 204 Bank overdrafts – – – 184 183 153 Bank debt1 1,261 1,164 1,148 131 Net debt 1,111 994 1,010 Lease
Slide 16: Ongoing Expansion of Asset-Light O&M Portfolio Drives Bottom-Line Growth
Ongoing Expansion of Asset-Light O&M Portfolio Drives Bottom-Line Growth O&M opportunities in the UAE and MENA On-going O&M projects Al • Stakeholder: ADNOC Group (Corporate) 96,000+ Approach Dhannah • Specifications: Multi-specialty hospital in Al Dhafrah, Abu Dhabi Patient footfall Hospital • Esta
Slide 17: Guidance
Guidance Leading Super-Specialty Healthcare Provider in MENA
Slide 18: Mid-Term Outlook Reiterated, FY'24 Guidance Updated
Mid-Term Outlook Reiterated, FY'24 Guidance Updated FY 2024 (Expected) Mid-term (2025-2027) • UAE: +1 medical center, +2 day surgery centers, • UAE: +1 hospital in Dubai & +1 medical center Expansion +10 primary care clinics, +22 additional beds • KSA: +32 PhysioTherabia centers, • KSA: +24 PhysioTh
Slide 19: Q&A Appendix
Q&A Appendix Leading Super-Specialty Healthcare Provider in MENA
Slide 20: Business model
1 2 Business 1 Differentiating capabilities model • Level I & II Trauma Center • Centralised Lab Serving all • Level III Tertiary NICU • Nuclear Medicine socio-economic • Physio & Rehab Care • Department of Thalassemia groups • Intraoperative MRI • Advanced Center for Research • Da Vinci Xi robotic
Slide 21: Group & Segment Summary
Group & Segment Summary Group financial summary Segmental financial summary2 AED millions Q3’24 Q3’23 9M’24 9M‘23 AED millions Q3’24 Q3’23 9M’24 9M‘23 Revenue 1,319 1,155 3,705 3,317 Revenue 1,319 1,155 3,705 3,317 Inventories consumed (336) (290) (941) (807) Hospitals3 1,161 1,028 3,255 2,945 Docto
Slide 22: Investor Relations
Investor Relations November 2024 Sergei Levitskii Director of Investor Relations sergei.levitskii@burjeelholdings.com T: +971 2 3041 111 ir@burjeelholdings.com F: +971 2 2222 363 M: +971 503802383 PO Box 7400, Abu Dhabi, UAE Investor Calendar Company Website